The potential of biology-guided radiation therapy in thoracic cancer: A preliminary treatment planning study

Purpose We investigated the feasibility of biology-guided radiotherapy (BgRT), a technique that utilizes real-time positron emission imaging to minimize tumor motion uncertainties, to spare nearby organs at risk. Methods Volumetric modulated arc therapy (VMAT), intensity-modulated proton (IMPT) therapy, and BgRT plans were created for a paratracheal node recurrence (case 1; 60 Gy in 10 fractions) and a primary peripheral left upper lobe adenocarcinoma (case 2; 50 Gy in four fractions). Results For case 1, BgRT produced lower bronchus V40 values compared to VMAT and IMPT. For case 2, total lung V20 was lower in the BgRT case compared to VMAT and IMPT. Conclusions BgRT has the potential to reduce the radiation dose to proximal critical structures but requires further detailed investigation.

[1]  M. Surucu,et al.  Image-mode performance characterization of a positron emission tomography subsystem designed for Biology-guided radiotherapy (BgRT). , 2022, The British journal of radiology.

[2]  B. Archibald-Heeren,et al.  Varian ethos online adaptive radiotherapy for prostate cancer: Early results of contouring accuracy, treatment plan quality, and treatment time , 2021, Journal of applied clinical medical physics.

[3]  Joe Y. Chang,et al.  Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. , 2021, The Lancet. Oncology.

[4]  S. Shirvani,et al.  The technical design and concept of a PET/CT linac for biology-guided radiotherapy , 2021, Clinical and translational radiation oncology.

[5]  A Promising Approach , 2021 .

[6]  B. Yaremko,et al.  Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial , 2020, medRxiv.

[7]  K. Pienta,et al.  Online Prostate-Specific Membrane Antigen and Positron Emission Tomography–Guided Radiation Therapy for Oligometastatic Prostate Cancer , 2019, Advances in radiation oncology.

[8]  Michael Lock,et al.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial , 2019, The Lancet.

[9]  J. Lee,et al.  Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Anurag K. Singh,et al.  Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Bradley,et al.  Combining stereotactic body radiation therapy with immunotherapy: current data and future directions. , 2018, Translational lung cancer research.

[12]  Minsong Cao,et al.  Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer: A Promising Approach , 2018, Cureus.

[13]  Lone Hoffmann,et al.  Cardiac and respiration induced motion of mediastinal lymph node targets in lung cancer patients throughout the radiotherapy treatment course. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  Joe Y. Chang,et al.  Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy. , 2016, International journal of radiation oncology, biology, physics.

[15]  Joe Y. Chang,et al.  A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). , 2015, International journal of radiation oncology, biology, physics.

[16]  Osama Sabri,et al.  PET/MR in dementia and other neurodegenerative diseases. , 2015, Seminars in nuclear medicine.

[17]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  H. Yamashita,et al.  Radiation pneumonitis after stereotactic radiation therapy for lung cancer. , 2014, World journal of radiology.

[19]  Joe Y. Chang,et al.  Clinical Investigation : Thoracic Cancer Stereotactic Ablative Radiation Therapy for Centrally Located Early Stage or Isolated Parenchymal Recurrences of Non-Small Cell Lung Cancer : How to Fly in a “ No Fly Zone ” , 2022 .

[20]  R. Komaki,et al.  The Potential Role of Respiratory Motion Management and Image Guidance in the Reduction of Severe Toxicities Following Stereotactic Ablative Radiation Therapy for Patients with Centrally Located Early Stage Non-Small Cell Lung Cancer or Lung Metastases , 2014, Front. Oncol..

[21]  G. Ulaner,et al.  Identifying and distinguishing treatment effects and complications from malignancy at FDG PET/CT. , 2013, Radiographics : a review publication of the Radiological Society of North America, Inc.

[22]  M. Martel,et al.  Aortic dose constraints when reirradiating thoracic tumors. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  S. Neves,et al.  Necrosis of bronchus in lung cancer. , 2011, Journal of bronchology & interventional pulmonology.

[24]  Ke Sheng,et al.  Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. , 2010, International journal of radiation oncology, biology, physics.

[25]  Issam El-Naqa,et al.  Exploring feature-based approaches in PET images for predicting cancer treatment outcomes , 2009, Pattern Recognit..

[26]  Hiroki Shirato,et al.  STEREOTACTIC RADIATION THERAPY WORKSHOP Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional Study , 2007 .

[27]  George Starkschall,et al.  Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. , 2007, International journal of radiation oncology, biology, physics.

[28]  A. Mehta,et al.  Necrosis of the bronchus. Role of radiation. , 1995, Chest.